Drug Trial Radar · NCT03019406
A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa
Last checked: Nov 20, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
22
Actual
Start
Oct 12, 2017
Primary completion
Sep 30, 2019
Study completion Aug 10, 2027
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jan 12, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months, up to 17 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a multi-stage, phase 2, open-label, multicenter, multinational, ascending dose cohort, repeated intravenous (IV) infusion study of avalglucosidase alfa in pediatric patients with Infantile-Onset Pompe Disease (IOPD) who have been previously treated with alglucosidase alfa for a minimum of 6 months immediately prior to study entry and have demonstrated clinical decline or unsatisfactory clinical response.
Conditions
- Glycogen Storage Disease Type II-Pompe's Disease
Interventions
Avalglucosidase alfa (GZ402666)Drug
Pharmaceutical form: powder for concentrate for solution for infusion, Route of administration: IV
Alglucosidase alfa (GZ419829)Drug
Pharmaceutical form: powder for concentrate for solution for infusion, Route of administration: IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- PAP: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Treatment-emergent Adverse Events, and Adverse Event of Special Interest (AESI)Time frame: From Baseline to Week 25
- PAP: Number of Participants With Infusion-associated Reactions (IARs)Time frame: From Baseline to Week 25
Locations
12 sites in 5 countries. Site status is shown where the registry gives one.
Regional Medical Genetics Center of New York Site Number : 8400002
Valhalla, New York
Duke University Medical Center Site Number : 8400001
Durham, North Carolina
Seattle Childrens Hospital and Regional Medical Center- Site Number : 8400005
Seattle, Washington
Investigational Site Number : 2500004
Nantes, France
Investigational Site Number : 2500003
Paris, France
Investigational Site Number : 2500002
Paris, France
Investigational Site Number : 2500001
Tours, France
Investigational Site Number : 3920001
Fuchu-shi, Tokyo, Japan
Investigational Site Number : 3920002
Fuchu-shi, Tokyo, Japan
Investigational Site Number : 1580001
Hsinchu, Taiwan
Investigational Site Number : 8260002
Manchester, United Kingdom
Investigational Site Number : 8260001
London, London, City of, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.